NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/21/2025
Back to search
Official data from USPTO
KYSO ANTIBODIES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
KYSO ANTIBODIES
ST13
US500000079353559Class
1, 5, 42, 45
Filing
79353559
Registration
7292381
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
03/21/2025
Trademark type
Word
Nice classes
1, 5, 42, 45
Filing date
08/10/2022
Registration date
01/30/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/30/2024
Last transaction
01/30/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
65
Owner location
DK
Examiner
FLETCHER, TRACY L
Law office
M60
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Genmab A/S
Representatives
Max Vern Amster, Rothstein & Ebenstein LLP
Technical classification
Nice Classes
Class 1Class 5Class 42Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Biological preparations for use in industry and science for in vitro and in vivo scientific and industrial research and development with regard to diseases; biochemical preparations for in vitro and in vivo scientific research purposes with regard to diseases; biochemical reagents used for non-medical purposes in the nature of in vitro and in vivo scientific and industrial research with regard to diseases; chemicals for use in biotechnological product development in the nature of in vitro and in vivo industrial product development with regard to diseases; active chemical ingredients for use in the manufacture of pharmaceuticals for the treatment of cancerautoimmune diseasesinflammatory disorders
Class 5
Pharmaceutical and veterinary preparations including preparations based on antibodiesbi- and multi-specific antibodies as well as fragmentsderivatives and conjugates thereofpharmaceutical products for the prevention and treatment of disorders of the nervous systemthe immune systemthe cardio-vascular systemthe metabolic systemthe respiratory systemthe musculo-skeletal systemthe genitourinary system; Pharmaceutical and veterinary preparationsincluding preparations based on antibodiesbi- and multi- specific antibodies as well as fragmentsderivatives and conjugates thereoffor the treatment of cancerautoimmune diseasesinflammatory disorders
Class 42
Medicalscientific and biological research in the fields of antibodiesbi- and multi-specific antibodies as well as fragmentsderivatives and conjugates thereof and development of pharmaceutical products based on the same; chemical analysis; computer programmingprogramming of computers for the collection and processing of medical data for use in medical scientific researchdevelopment and therapy and scientific researchdevelopment and therapy with antibodies and bi- and multi- specific antibodies as well as fragmentsderivatives or conjugates of any of these
Class 45
Legal services relating to the exploitation of patents and licensing of intellectual property in the field of medicine
Publications
History of USPTO decisions and trademark events.
31 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/21/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/01/2024
FIMP
FINAL DISPOSITION PROCESSED
04/30/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/30/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/30/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
01/30/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/15/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
01/15/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/15/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/15/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/14/2023
PUBO
PUBLISHED FOR OPPOSITION
11/14/2023
GPNX
NOTIFICATION PROCESSED BY IB
11/13/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/25/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
10/25/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/25/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/12/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/07/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/06/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/06/2023
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
09/15/2023
RFNP
REFUSAL PROCESSED BY IB
05/24/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/04/2023
RFRR
REFUSAL PROCESSED BY MPU
05/03/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/15/2023
CNRT
NON-FINAL ACTION WRITTEN
03/14/2023
DOCK
ASSIGNED TO EXAMINER
03/13/2023
MAFR
APPLICATION FILING RECEIPT MAILED
11/01/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/28/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/27/2022
Continuous trademark protection
Get notified about every new filing that threatens KYSO ANTIBODIES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.